Saturday, 31 October 2026European Markets

KAUFMAN ET BROAD And BURELLE Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - kaufman et broad (kof.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
kaufman et broad (kof.pa) €27.00 9.38% 20.92%
burelle (bur.pa) €433.00 4.46% 7.58%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. kaufman et broad (kof.pa)

9.38% forward dividend yield and 20.92% return on equity

kaufman & broad s.a. operates as a property developer and builder in france. it designs, develops, builds, and sells single-family homes in communities, managed residences, offices, shops, hotels, and logistics platforms and business parks. the company was founded in 1968 and is headquartered in courbevoie, france.

earnings per share

as for profitability, kaufman et broad has a trailing twelve months eps of €3.1.

pe ratio

kaufman et broad has a trailing twelve months price to earnings ratio of 8.71. meaning, the purchaser of the share is investing €8.71 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.92%.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 9, 2024, the estimated forward annual dividend rate is 2.4 and the estimated forward annual dividend yield is 9.38%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, kaufman et broad's stock is considered to be overbought (>=80).

more news about kaufman et broad.

2. burelle (bur.pa)

4.46% forward dividend yield and 7.58% return on equity

burelle sa, through its subsidiaries, offers automotive equipment, intelligent body systems, and clean energy systems and modules in france and internationally. the company offers plastic and composite body parts and systems, and fuel and pollution control systems; researches and develops lightweight vehicles, pollution control systems, and support for new engines; and develops, assembles, and provides logistics for automotive front-end modules. it also operates a venture capital company that invests in various companies through a network of family offices, investment funds, and financial institutions; and owns an office building in levallois, as well as various real estate assets in the lyon region. burelle sa was founded in 1957 and is headquartered in lyon, france.

earnings per share

as for profitability, burelle has a trailing twelve months eps of €63.32.

pe ratio

burelle has a trailing twelve months price to earnings ratio of 6.84. meaning, the purchaser of the share is investing €6.84 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.58%.

volatility

burelle's last week, last month's, and last quarter's current intraday variation average was a negative 0.55%, a negative 1.05%, and a positive 1.50%.

burelle's highest amplitude of average volatility was 0.96% (last week), 1.62% (last month), and 1.50% (last quarter).

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 28, 2024, the estimated forward annual dividend rate is 16 and the estimated forward annual dividend yield is 4.46%.

more news about burelle.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com